

November 2, 2022



# Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

## Presentation Details:

### **Credit Suisse 31st Annual Healthcare Conference**

Format: Presentation

Date: Wednesday, November 9, 2022

Time: 11:35 a.m. ET / 8:35 a.m. PT

Location: Rancho Palos Verdes, CA

### **Jefferies London Healthcare Conference**

Format: Presentation

Date: Thursday, November 17, 2022

Time: 12:55 p.m. GMT / 7:55 a.m. ET / 4:55 a.m. PT

Location: London

The presentations will be accessible through the News & Events page of the Investor Relations section of the company's website at [www.sutrobio.com](http://www.sutrobio.com). Archived replays will be available for at least 30 days after the event.

## **About Sutro Biopharma**

Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolR $\alpha$ )-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro's platform technology also enabled the spin out of Vaxcyte and the creation of VAX-24, a 24-valent pneumococcal conjugate vaccine in clinical studies for

the prevention of invasive pneumococcal disease. Sutro's rational design and precise protein engineering has enabled six product candidates in the clinic. Follow Sutro on Twitter, @SutroBio, and at [www.sutro.bio.com](http://www.sutro.bio.com) to learn more about our passion for changing the future of oncology.

**Investor Contact**

Annie J. Chang  
Sutro Biopharma  
(650) 801-5728  
[ajchang@sutro.bio.com](mailto:ajchang@sutro.bio.com)

**Media Contact**

Amy Bonanno  
Solebury Strategic Communications  
(914) 450-0349  
[abonanno@soleburystrat.com](mailto:abonanno@soleburystrat.com)



Source: Sutro Biopharma, Inc.